Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | F11 | P03951 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.47 |
| ▸ | HMGCR | P04035 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35382 | 1.00 | PTPN1 (0.52) | PTPN1PTPN2PTPN11USP2MEN1 | |
| SCHEMBL34887 | 1.00 | PTPN1 (0.52) | PTPN1PTPN2PTPN11USP2MEN1 | |
| SCHEMBL19460956 | 0.92 | PTPN1 (0.49) | PTPN1PTPN2PTPN11USP2MEN1 | |
| SCHEMBL8350379 | 0.89 | PTPN1 (0.53) | PTPN1PTPN2PTPN11USP2MEN1 | |
| SCHEMBL8350378 | 0.89 | PTPN1 (0.53) | PTPN1PTPN2PTPN11USP2MEN1 | |
| SCHEMBL9179303 | 0.88 | PTPN1 (0.52) | PTPN1PTPN2PTPN11USP2MEN1 | |
| SCHEMBL14103196 | 0.88 | PTPN1 (0.52) | PTPN1PTPN2PTPN11USP2MEN1 | |
| SCHEMBL7980742 | 0.87 | PTPN1 (0.51) | PTPN1PTPN2PTPN11USP2MEN1 | |
| SCHEMBL8348286 | 0.87 | PTPN1 (0.51) | PTPN1PTPN2PTPN11USP2MEN1 | |
| SCHEMBL8348283 | 0.87 | PTPN1 (0.51) | PTPN1PTPN2PTPN11USP2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772463-B2 | Fluorescent dye-labeled glucose bioprobe, synthesis method and usage thereof | SNU R&DB FOUNDATION (KR) | 2014-07-08 | — | — | US | disclosed |
| US-8679854-B2 | Fluorescent dye-labeled glucose bioprobe, synthesis method and usage thereof | SNU & DB FOUNDATION (KR) | 2014-03-25 | — | — | US | disclosed |
| US-8679854-B2 | Fluorescent dye-labeled glucose bioprobe, synthesis method and usage thereof | SNU & DB FOUNDATION (KR) | 2014-03-25 | — | — | US | disclosed |
| US-8632749-B2 | Two photon tracer, method for the preparation thereof and the use thereof in screening anticancer agents | SNU R&DB FOUNDATION (KR) | 2014-01-21 | — | — | US | disclosed |
| US-20110059022-A1 | TWO PHOTON TRACER, METHOD FOR THE PREPARATION THEREOF AND THE USE THEREOF IN SCREENING ANTICANCER AGENTS | SNU R&DB FOUNDATION (KR) | 2011-03-10 | — | — | US | disclosed |
| US-20110059477-A1 | FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF | SNU R&DB FOUNDATION (KR) | 2011-03-10 | — | — | US | disclosed |
| US-20100105149-A1 | FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF | SNU R&DB FOUNDATION (KR) | 2010-04-29 | — | — | US | disclosed |
| US-20100105149-A1 | FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF | SNU R&DB FOUNDATION (KR) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059477-A1 | FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF | OGA, UGGT1, GALE | PTPN1 2831/4885PTPN2 4200/4885PTPN11 3426/4885 |
| US-20100105149-A1 | FLUORESCENT DYE-LABELED GLUCOSE BIOPROBE, SYNTHESIS METHOD AND USAGE THEREOF | GALE, OGA, GNE | PTPN1 3229/4885PTPN2 3854/4885PTPN11 3389/4885 |
| US-20110059022-A1 | TWO PHOTON TRACER, METHOD FOR THE PREPARATION THEREOF AND THE USE THEREOF IN SCREENING ANTICANCER AGENTS | SLC2A2, SLC2A1, SLC2A9 | PTPN1 4467/4885PTPN2 4040/4885PTPN11 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.